Anti-PSCA antibodies
US6790939B2 · kind B2 · utility
19Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 14, 2001 |
| Grant date | Sep 14, 2004 |
| Priority date | — |
| Expiry date | May 14, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/705
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.